Physician profile
Charles Welly
NPI 1700956414
$1,503.29
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $541 · 2021: $496 · 2022: $27.73.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $324.11 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.88 | 2019-2021 | |
| Amgen INC. | $186.85 | 2019-2020 | |
| Amarin Pharma, INC. | $152.56 | 2019-2021 | |
| Glaxosmithkline, LLC. | $130.14 | 2019-2021 | |
| Lilly USA, LLC | $118.60 | 2019-2021 | |
| Pfizer INC. | $100.88 | 2020-2021 | |
| Abbvie INC. | $76.20 | 2021-2022 | |
| Eisai INC. | $55.45 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.04 | 2020-2021 | |
| Ge Healthcare | $30.91 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $30.09 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.23 | 2021 | |
| Abbott Laboratories | $17.73 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.33 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11.29 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Welly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.